Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03222427 | A Study of LY3314814 in Healthy Participants | PHASE1 | COMPLETED | 8 | — | — | Jan 15, 2018 | Feb 16, 2018 | Oct 31, 2019 | 1 | United Kingdom |
Absolute bioavailability was quantified using a mixed-effects analysis of variance (ANOVA) model applied to the log-transformed dose-normalized AUC(0-∞) of LY3314814 oral dosing and IV administered \[13C415N3\]-LY3314814.
| Arm | Type | Description |
|---|---|---|
| LY3314814 | EXPERIMENTAL | Single 50 milligram (mg) dose of LY3314814 administered orally |
| [13C415N3] LY3314814 | EXPERIMENTAL | Single 100 micrograms (μg) intravenous (IV) dose of \[13C415N3\] LY3314814 administered as an IV infusion. |
| Name | Type | Description |
|---|---|---|
| LY3314814 | DRUG | Administered orally |
| [13C415N3] LY3314814 | DRUG | Administered as an IV infusion |
Inclusion Criteria: * Are overtly healthy males or females * Have venous access sufficient to allow for blood sampling and intravenous (IV) administration of the investigational product Exclusion Criteria: * Have a history of significant ophthalmic disease * Have vitiligo or any other clinically ...